RxDoctor Payments Data

Michael Marvi, MD

Neurology · Burbank, CANPI 1205054129

Payments from drug & device makers

$5,970in general payments, 2019–2025

Across 92 payments — averaging $64.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Portola Pharmaceuticals, LLC$355
  • Boston Scientific$316
  • Amgen$284
  • Acadia Pharmaceuticals Inc$214
  • Biogen$175
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$2,45041%
  • Speaking & faculty fees$461%
  • Travel & lodging$3686%
  • Food & beverage$3,05351%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,970 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$124,036
Medicare patients
401
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$53,956
Nurtec OdtRimegepant Sulfate17$32,961
Memantine Hcl ErMemantine Hcl75$11,730
Carbidopa37$9,355
Carbidopa-LevodopaCarbidopa/Levodopa271$9,202
Rasagiline Mesylate45$6,882
Carbidopa-Levodopa ErCarbidopa/Levodopa41$5,583
Entacapone19$4,748
AmantadineAmantadine Hcl18$1,754
RivastigmineRivastigmine Tartrate11$1,288
Duloxetine Hcl30$818
Ropinirole Hcl23$688
Pramipexole DihydrochloridePramipexole Di-Hcl18$541
Levetiracetam17$449
Divalproex Sodium12$389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$118$53,95611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →